Search results for "Propionate"

showing 10 items of 144 documents

Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD

2000

ss(2)-Agonists and corticosteroids or theophylline can interact to produce beneficial effects on airway function in asthma, but this has not been established in COPD.Eighty patients with well-controlled COPD were randomized to receive 3 months of treatment in one of four treatment groups: (1) salmeterol, 50 microg bid; (2) salmeterol, 50 microg, plus fluticasone propionate, 250 microg bid; (3) salmeterol, 50 microg, plus fluticasone propionate, 500 microg bid; and (4) salmeterol, 50 microg, plus titrated theophylline bid. At each visit, a dose-response curve to inhaled salbutamol was constructed using a total cumulative dose of 800 microg.A gradual increase in FEV(1) was observed with each …

MalePulmonary and Respiratory Medicinemedicine.drug_classPharmacologyCritical Care and Intensive Care MedicineFluticasone propionateTheophyllineForced Expiratory VolumeBronchodilatorAdministration InhalationmedicineHumansAlbuterolTheophyllineLung Diseases ObstructiveGlucocorticoidsSalmeterol XinafoateAgedFluticasoneDose-Response Relationship Drugbusiness.industryDrug SynergismAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerBronchodilator AgentsAndrostadienesAnesthesiaSalbutamolFluticasoneCorticosteroidDrug Therapy CombinationFemaleSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Fluticasone in mild to moderate atopic dermatitis relapse: A randomized controlled trial

2018

Background: The long-term efficacy of corticosteroids to prevent atopic dermatitis (AD) relapses has partially been addressed in children. This study compared an intermittent dosing regimen of fluticasone propionate (FP) cream 0.05% with its vehicle base in reducing the risk of relapse in children with stabilized AD. Methods A randomized controlled, multicentric, double-blind trial was conducted. Children (2-10 years) with mild/moderate AD (exclusion criteria: > 30% affected body surface area and/or head) were enrolled into an Open-label Stabilization Phase (OSP) of up to 2 weeks on twice daily FP. Those who achieved treatment success entered the Double-blind Maintenance Phase (DMP). They w…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyImmunologyAnti-Inflammatory AgentsLower riskFluticasone propionateIntermittent dosingFluticasone propionateDermatitis Atopiclaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallaw030225 pediatricsInternal medicineSecondary PreventionmedicineAtopic dermatitis Clinical trial Fluticasone propionate Intermittent dosing PreventionHumansImmunology and AllergyChildFluticasoneAtopic dermatitisBody surface areabusiness.industryPreventionGeneral MedicineAtopic dermatitismedicine.diseaseClinical trialRegimenChild PreschoolRelative riskFluticasoneFemalebusinessmedicine.drug
researchProduct

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) comp…

2019

Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronchi by adressing both muscarinic acetylcholine receptors and β2-adrenoceptor. However, the anti-inflammatory effects of the AZD8999 monotherapy or in combination with corticosteroids are unknown. This study investigates the anti-inflammatory effects of AZD8999 in monotherapy and combined with fluticasone propionate in neutrophils from healthy and chronic obstructive pulmonary disease (COPD) patients. Peripheral blood neutrophils from healthy and C…

MalePulmonologyNeutrophilsPhysiologyAnti-Inflammatory AgentsPharmacologyPathology and Laboratory MedicineBiochemistryPulmonary Disease Chronic ObstructiveWhite Blood CellsGlucocorticoid receptorAnimal CellsMuscarinic acetylcholine receptorMedicine and Health SciencesPost-Translational ModificationPhosphorylationReceptorImmune ResponseMultidisciplinaryPharmaceuticsQRDrug SynergismMiddle AgedReceptors MuscarinicHealthy VolunteersBody FluidsChemistryBloodPhysical SciencesQuinolinesMedicineDrug Therapy CombinationFemalemedicine.symptomCellular TypesAnatomymedicine.drugResearch ArticleSignal TransductionAgonistTransmembrane Receptorsmedicine.drug_classp38 mitogen-activated protein kinasesChronic Obstructive Pulmonary DiseaseImmune CellsScienceImmunologyInflammationMuscarinic AntagonistsThiophenesFluticasone propionateSigns and SymptomsDrug TherapyCyclohexanesDiagnostic MedicinemedicineHumansAdrenergic beta-2 Receptor AgonistsAgedInflammationBlood CellsDose-Response Relationship Drugbusiness.industryAntagonistChemical CompoundsBiology and Life SciencesProteinsCell BiologyAcetylcholine ReceptorsFluticasoneMuscarinic Acetylcholine ReceptorsReceptors Adrenergic beta-2PropionatesbusinessReceptor Antagonist TherapyPLoS ONE
researchProduct

Comparative Effect of Beclomethasone Dipropionate and Cetirizine on Acoustic Rhinometry Parameters in Children With Perennial Allergic Rhinitis: A Ra…

2018

Background and objectives The effect of intranasal corticosteroids and oral antihistamines on acoustic rhinometry parameters has not been directly compared. The primary objective was to compare the effect of a 21-day course of treatment with nasal beclomethasone dipropionate (nBDP) with that of cetirizine (CTZ) on nasal patency measured using acoustic rhinometry in children with perennial allergic rhinitis (PAR). The secondary objective was to compare the effect of both drugs on nasal cytology, symptom severity, sleep quality, and quality of life. Methods In this 21-day, open-label, randomized controlled study, 34 children with PAR (age 6-14 years) with a Total 5-Symptom Score (T5SS) ≥5 rec…

MaleRhinometry Acousticmedicine.medical_specialtyRhinitis Allergic PerennialAdolescentNasal patencyNostrilImmunologyAnti-Inflammatory AgentsGastroenterologyAllergic rhinitislaw.inventionPittsburgh Sleep Quality Index03 medical and health sciences0302 clinical medicineAcoustic rhinometryRandomized controlled trialQuality of lifelawInternal medicineSurveys and QuestionnairesAllergic rhinitimedicineImmunology and AllergyHumans030212 general & internal medicineChildBeneficial effectsChildrenAdministration Intranasalbusiness.industryBeclomethasoneCetirizineCetirizineBeclomethasone dipropionatemedicine.anatomical_structureQuality of LifeNasal administrationFemaleAcoustic rhinometrybusiness030217 neurology & neurosurgerymedicine.drugJournal of investigational allergologyclinical immunology
researchProduct

Assessing biomarkers in a real-world severe asthma study (ARIETTA)

2016

AbstractThe prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA (NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study designed to assess the relationship between asthma biomarkers and disease-related health outcomes. The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication are to be included. In this real-world study, patients will be treated according to the…

MaleSevere asthmaCardiac & Cardiovascular SystemsExacerbationAIRWAY INFLAMMATIONRespiratory SystemEosinophilSeverity of Illness Indexlaw.inventionDOUBLE-BLIND0302 clinical medicineQuality of lifeRandomized controlled trialAdrenal Cortex HormoneslawForced Expiratory VolumeProspective Studies030212 general & internal medicineProspective cohort studyFluticasoneEPITHELIAL-CELLSExacerbationRANDOMIZED CONTROLLED-TRIALPrognosis3. Good healthTO-SEVERE ASTHMAFemaleLife Sciences & Biomedicinemedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyPHENOTYPESNitric Oxide1102 Cardiovascular Medicine And HaematologyFluticasone propionate03 medical and health sciencesPredictive Value of TestsAdministration InhalationSeverity of illnessmedicineHumansNITRIC-OXIDE SYNTHASEIntensive care medicineCOMBINATIONAsthmaScience & Technologybusiness.industryPULMONARY-FUNCTION1103 Clinical SciencesBiomarkerImmunoglobulin Emedicine.diseaseAsthmarespiratory tract diseasesEosinophilsBiomarker; Eosinophil; Exacerbation; Periostin; Severe asthma; Pulmonary and Respiratory MedicinePeriostin030228 respiratory systemQuality of LifeCardiovascular System & CardiologyFluticasonebusinessCell Adhesion MoleculesBiomarkersRespiratory Medicine
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

BCL-2 UPREGULATION AFTER 3-NITROPROPIONIC ACID PRECONDITIONING IN WARM RAT LIVER ISCHEMIA

2008

We aimed to determine whether 3-nitropropionic acid (3-NPA) preconditioning protects rat livers against warm ischemia/reperfusion injury. We hypothesized that 3-NPA mediates its protective effects by Bcl-2 upregulation. Brown-Norway rats (200 g) were injected with 3-NPA (10 mg/kg intraperitoneally) 24 h before 90 min of selective warm in situ ischemia. In additional experiments, 30-day survival was studied after 90 min of warm liver ischemia and resection of nonischemic liver tissue. We demonstrate increased mRNA and protein levels of Bcl-2 by real-time polymerase chain reaction, immunohistochemistry, and Western blot analysis in 3-NPA-pretreated rats. All treated animals survived, whereas …

Malemedicine.medical_specialtyBlotting WesternIschemiaCritical Care and Intensive Care MedicineLipid peroxidationchemistry.chemical_compoundstomatognathic systemWestern blotDownregulation and upregulationInternal medicinemedicineAnimalsWarm IschemiaIschemic PreconditioningCaspasechemistry.chemical_classificationReactive oxygen speciesmedicine.diagnostic_testbiologyCaspase 3Reverse Transcriptase Polymerase Chain ReactionNitro Compoundsmedicine.diseaseImmunohistochemistryCaspase 9RatsEndocrinologyLiverProto-Oncogene Proteins c-bcl-2chemistryApoptosisReperfusion InjuryEmergency Medicinebiology.proteinPropionatesReperfusion injuryShock
researchProduct

Topical treatment of oral lichen planus with anthocyanins

2014

Background: Oxidative stress is involved in oral lichen planus (OLP) pathogenesis; meanwhile anthocyanins are natural antioxidants present in grapes skin. Objectives: The aim of this research was to verify the utility of anthocyanins, extracted from grapes skin, for the local treatment of oral lichen planus and to compare it with clobetasol propionate- neomycin -nystatin cream (CP-NN). Study Design: Prospective, non-randomized study, with control group. Fifty-two patients with OLP were includ - ed. We divided patients into two categories: erosive oral lichen planus (EOLP) and non erosive oral lichen planus (NEOLP). 38 had EOLP (17 cases and 21 controls) and 14 presented NEOLP types (9 cases…

Malemedicine.medical_specialtyNystatinAdministration TopicalTopical treatmentOdontologíamedicine.disease_causeAnthocyaninsstomatognathic systemmedicineHumansProspective StudiesOral mucosaProspective cohort studyGeneral DentistryClobetasolOral Medicine and Pathologybusiness.industryResearchSignificant differencefungifood and beveragesNeomycinMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludSurgeryDrug Combinationsstomatognathic diseasesmedicine.anatomical_structureNystatinOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryOral lichen planusFemaleClobetasol propionatebusinessOxidative stressmedicine.drugLichen Planus Oral
researchProduct

Early-onset tolerance in rat global cerebral ischemia induced by a mitochondrial inhibitor

2000

It was studied whether a subtoxic dose of the mitochondrial neurotoxin, 3-nitropropionic acid (3-NPA), can initiate early-onset tolerance induction for subsequent ischemic injury. Wistar rats were pretreated for 3 h by intraperitoneal 3-NPA (20 mg/kg body weight; n=13) or solvent (n=12). Fifteen minutes global cerebral ischemia was induced by bilateral carotid artery occlusion and hypobaric hypotension. rCBF and tissue hemoglobin oxygen saturation were measured by laser Doppler scanning and a microspectrophotometric method. Ischemic insult and brain temperature were identical in both groups. Body weight and neurological scores recovered in the pretreated group but further deteriorated in th…

Malemedicine.medical_specialtyTime FactorsNeurotoxinsIschemiaConvulsantsMotor ActivityHippocampal formationBrain IschemiaCentral nervous system diseaseBrain ischemiaProsencephalonInternal medicinemedicineAnimalsNeurotoxinRats WistarNeuronsNeocortexbusiness.industryGeneral NeuroscienceNitro Compoundsmedicine.diseaseMitochondriaRatsTolerance inductionNeuroprotective Agentsmedicine.anatomical_structureEndocrinologyReperfusion InjuryAnesthesiaPropionatesbusinessReperfusion injuryNeuroscience Letters
researchProduct

Polyaspartamide-based nanoparticles loaded with fluticasone propionate and the in vitro evaluation towards cigarette smoke effects

2017

This paper describes the evaluation of polymeric nanoparticles (NPs) as a potential carrier for lung administration of fluticasone propionate (FP). The chosen polymeric material to produce NPs was a copolymer based on α,β-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) whose backbone was derivatised with different molecules, such as poly(lactic acid) (PLA) and polyethylenglycol (PEG). The chosen method to produce NPs from PHEA-PLA-PEG2000 was the method based on high-pressure homogenization and subsequent solvent evaporation by adding Pluronic F68 during the process and trehalose before lyophilisation. Obtained colloidal FP-loaded NPs showed a slightly negative surface charge and nanometric d…

Materials scienceFluticasone propionate (FP)General Chemical EngineeringNanoparticle02 engineering and technologyPolymeric nanoparticle010402 general chemistry01 natural sciencesαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA)Articlealpha beta-poly-(N-2-hydroxyethyl)-D L-aspartamide (PHEA)">dPoly(lactic acid) (PLA)lcsh:ChemistryColloidchemistry.chemical_compoundPEG ratioCopolymer?Organic chemistryGeneral Materials ScienceSurface charge?-poly-(N-2-hydroxyethyl)-dαβ-poly-(N-2-hydroxyethyl)-technology industry and agriculture">l-aspartamide (PHEA)Poly(ethylene glycol) (PEG)respiratory system021001 nanoscience & nanotechnologyTrehaloseIn vitro0104 chemical sciencesLactic acidαβ-poly-(<i>N</i>-2-hydroxyethyl)-<span style="font-variant: small-caps;">d</span><span style="font-variant: small-caps;">l</span>-aspartamide (PHEA); poly(lactic acid) (PLA); poly(ethylene glycol) (PEG); polymeric nanoparticles; fluticasone propionate (FP)polymeric nanoparticleschemistrylcsh:QD1-999l-aspartamide (PHEA); poly(lactic acid) (PLA); poly(ethylene glycol) (PEG); polymeric nanoparticles; fluticasone propionate (FP)0210 nano-technologyNuclear chemistry
researchProduct